Your browser doesn't support javascript.
loading
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Wilhelm-Benartzi, Charlotte S; Miller, Sarah E; Bruggraber, Sylvaine; Picton, Diane; Wilson, Mark; Gatley, Katrina; Chhabra, Anita; Marcovecchio, M Loredana; Hendriks, A Emile J; Morobé, Hilde; Chmura, Piotr Jaroslaw; Bond, Simon; Aschemeier-Fuchs, Bärbel; Knip, Mikael; Tree, Timothy; Overbergh, Lut; Pall, Jaivier; Arnaud, Olivier; Haller, Michael J; Nitsche, Almut; Schulte, Anke M; Mathieu, Chantal; Mander, Adrian; Dunger, David.
Afiliação
  • Wilhelm-Benartzi CS; Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK Wilhelm-BenartziC@cardiff.ac.uk.
  • Miller SE; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Bruggraber S; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Picton D; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Wilson M; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Gatley K; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Chhabra A; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Marcovecchio ML; Pharmacy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Hendriks AEJ; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Morobé H; Department of Paediatrics, University of Cambridge, Cambridge, UK.
  • Chmura PJ; Katholieke Universiteit Leuven/ Universitaire Ziekenhuizen, Leuven, Belgium.
  • Bond S; Center for Protein Research, Kobenhavns Universitet Sundhedsvidenskabelige Fakultet, Kobenhavn, Denmark.
  • Aschemeier-Fuchs B; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Knip M; Diabetes Centre for Children and Adolescents, Children's Hospital Auf der Bult, Hannover, Germany.
  • Tree T; Research Program for Clinical and Molecular Metabolism, University of Helsinki Faculty of Medicine, Helsinki, Finland.
  • Overbergh L; Pediatric Research Centre, University of Helsinki Children's Hospital, Helsinki, Finland.
  • Pall J; Department of Immunobiology, King's College London, London, UK.
  • Arnaud O; Katholieke Universiteit Leuven/ Universitaire Ziekenhuizen, Leuven, Belgium.
  • Haller MJ; INNODIA Patient Advisory Committee, Madrid, Spain.
  • Nitsche A; INNODIA Patient Advisory Committee, Paris, France.
  • Schulte AM; Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
  • Mathieu C; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Mander A; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Dunger D; Katholieke Universiteit Leuven/ Universitaire Ziekenhuizen, Leuven, Belgium.
BMJ Open ; 11(12): e053669, 2021 12 07.
Article em En | MEDLINE | ID: mdl-34876434
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Adolescent / Adult / Child / Humans / Middle aged Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Adolescent / Adult / Child / Humans / Middle aged Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido